ABIVAX Société Anonyme (NASDAQ:ABVX) Receives $32.00 Average PT from Brokerages

ABIVAX Société Anonyme (NASDAQ:ABVX) has been assigned a consensus recommendation of “Moderate Buy” from the six brokerages that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $34.20.

A number of equities analysts have recently commented on ABVX shares. BTIG Research assumed coverage on ABIVAX Société Anonyme in a report on Monday, May 20th. They issued a “buy” rating and a $43.00 price objective for the company. Piper Sandler began coverage on ABIVAX Société Anonyme in a research note on Monday, April 29th. They issued an “overweight” rating and a $42.00 price target for the company. Guggenheim started coverage on ABIVAX Société Anonyme in a research note on Monday, April 29th. They set a “buy” rating and a $50.00 price objective on the stock. Finally, Morgan Stanley increased their price objective on ABIVAX Société Anonyme from $15.00 to $16.00 and gave the company an “equal weight” rating in a report on Thursday, April 11th.

Hedge Funds Weigh In On ABIVAX Société Anonyme

A number of large investors have recently made changes to their positions in the company. BNP Paribas Financial Markets acquired a new stake in ABIVAX Société Anonyme during the first quarter worth approximately $81,000. Capstone Investment Advisors LLC acquired a new position in ABIVAX Société Anonyme during the fourth quarter worth about $618,000. Ghisallo Capital Management LLC bought a new position in ABIVAX Société Anonyme in the 4th quarter valued at approximately $642,000. Kennedy Capital Management LLC lifted its stake in shares of ABIVAX Société Anonyme by 35.3% in the 1st quarter. Kennedy Capital Management LLC now owns 120,168 shares of the company’s stock valued at $1,718,000 after acquiring an additional 31,331 shares during the last quarter. Finally, Rosalind Advisors Inc. acquired a new stake in shares of ABIVAX Société Anonyme during the first quarter valued at about $5,411,000. Institutional investors own 47.91% of the company’s stock.

ABIVAX Société Anonyme Stock Performance

Shares of ABVX opened at $13.86 on Monday. ABIVAX Société Anonyme has a 12 month low of $7.99 and a 12 month high of $17.02. The firm has a fifty day simple moving average of $14.69 and a 200 day simple moving average of $12.73.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.